{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:53:56Z","timestamp":1787741636818,"version":"build-2784847793"},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1683","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>The FDA has approved a subcutaneously injected, extended-release formulation of the mu-opioid receptor partial agonist and kappa-opioid receptor antagonist buprenorphine (Brixadi \u2013 Braeburn) for once-weekly or once-monthly treatment of moderate to severe opioid use disorder.<\/jats:p>","DOI":"10.58347\/tml.2023.1683c","type":"journal-article","created":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T15:26:59Z","timestamp":1694014019000},"page":"133-135","source":"Crossref","is-referenced-by-count":1,"title":["Once-Weekly or Once-Monthly Subcutaneous Buprenorphine (Brixadi) for Opioid Use Disorder"],"prefix":"10.58347","volume":"65","author":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"37151","published-online":{"date-parts":[[2023,8,21]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T15:26:59Z","timestamp":1694014019000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1683c"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,21]]},"references-count":0,"journal-issue":{"issue":"1683","published-online":{"date-parts":[[2023,8,21]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2023.1683c","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,21]]}}}